161 related articles for article (PubMed ID: 9007858)
1. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
Kaba SE; DeMonte F; Bruner JM; Kyritsis AP; Jaeckle KA; Levin V; Yung WK
Neurosurgery; 1997 Feb; 40(2):271-5. PubMed ID: 9007858
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alfa-2b for meningioma.
Wöber-Bingöl C; Wöber C; Marosi C; Prayer D
Lancet; 1995 Feb; 345(8945):331. PubMed ID: 7837901
[No Abstract] [Full Text] [Related]
5. Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.
Chohan MO; Ryan CT; Singh R; Lanning RM; Reiner AS; Rosenblum MK; Tabar V; Gutin PH
Neurosurgery; 2018 Jun; 82(6):824-832. PubMed ID: 28645194
[TBL] [Abstract][Full Text] [Related]
6. Recurrent meningioma.
Boylan SE; McCunniff AJ
Cancer; 1988 Apr; 61(7):1447-52. PubMed ID: 3278800
[TBL] [Abstract][Full Text] [Related]
7. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.
Chang SM; Barker FG; Huhn SL; Nicholas MK; Page M; Rabbitt J; Prados MD
J Neurooncol; 1998 Apr; 37(2):169-76. PubMed ID: 9524096
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
Sioka C; Kyritsis AP
J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
[TBL] [Abstract][Full Text] [Related]
9. Management of Atypical and Anaplastic Meningiomas.
Buttrick S; Shah AH; Komotar RJ; Ivan ME
Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
Chamberlain MC; Glantz MJ
Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
12. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.
Chamberlain MC
CNS Oncol; 2013 May; 2(3):227-35. PubMed ID: 25054463
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
[TBL] [Abstract][Full Text] [Related]
14. MR-guided laser interstitial thermal therapy in the treatment of recurrent intracranial meningiomas.
Rammo R; Scarpace L; Nagaraja T; Lee I
Lasers Surg Med; 2019 Mar; 51(3):245-250. PubMed ID: 30592538
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
Strassner C; Buhl R; Mehdorn HM
Neurol Res; 2009 Jun; 31(5):478-82. PubMed ID: 19500450
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for meningiomas.
Kyritsis AP
J Neurooncol; 1996 Sep; 29(3):269-72. PubMed ID: 8858533
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
18. Pediatric meningiomas: 65-year experience at a single institution.
Grossbach AJ; Mahaney KB; Menezes AH
J Neurosurg Pediatr; 2017 Jul; 20(1):42-50. PubMed ID: 28474981
[TBL] [Abstract][Full Text] [Related]
19. Management of benign and aggressive intracranial meningiomas.
Akeyson EW; McCutcheon IE
Oncology (Williston Park); 1996 May; 10(5):747-56; discussion 756-9. PubMed ID: 8738830
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
